Phathom Pharmaceuticals Refocuses on Gastroenterology, Projects Profitability by Second Half 2026
核心洞察
Phathom Pharmaceuticals has strategically pivoted from primary care to gastroenterology-focused sales for VOQUEZNA, the first potassium-competitive acid blocker (搜索) approved in the U.S. for GERD (搜索).
The company generated $55 million in revenue in 2024 and estimates $175 million for 2025, targeting operating profitability in the second half of 2026.
CEO Steven Basta outlined plans to capture 20-30% of gastroenterology PPI (搜索) prescriptions, potentially generating $1 billion in revenue from GI practices alone.
Phathom Pharmaceuticals has executed a strategic commercial pivot toward gastroenterology specialists, positioning the company to achieve operating profitability in the second half of 2026, CEO Steven Basta announced at the Guggenheim Emerging Outlook Biotech Summit.
The company's refocused strategy centers on VOQUEZNA (vonoprazan), described by Basta as "the first-to-market potassium-competitive acid blocker (搜索) (P-CAB) in the U.S. for gastroesophageal reflux disease (GERD (搜索))." The drug targets patients who remain symptomatic on existing therapies, with Basta noting that "roughly 40% of reflux patients on standard-of-care therapy are still in pain and represent an addressable group for a stronger acid suppression option."
Commercial Performance and Growth Trajectory
VOQUEZNA launched in November 2023, generating $55 million in revenue during its first full year on the market in 2024. For 2025, Phathom estimates revenue of $175 million, representing significant year-over-year growth. Basta reiterated the company's expectation to "transition to operating profitability during 2026" with "positive operating profit" in the second half of the year.
The strategic shift away from primary care toward gastroenterology specialists involved several key operational changes throughout 2025. In May, Phathom announced its realignment toward gastroenterology. July brought changes to salesforce target lists, adding remaining gastroenterologists while removing what Basta described as "unproductive primary care targets." By October, the company had remapped sales territories to better balance gastroenterology targets after identifying that earlier territory designs were built around primary care.
Despite potential disruption from these changes, Basta said the company "continued to grow through the fourth quarter," which he described as "confidence-inspiring going into 2026." The company expects to reach a "full-strength" sales organization of approximately 300 sales representatives by the end of March.
Market Opportunity and Revenue Projections
Basta outlined substantial market opportunity within gastroenterology practices. The company previously referenced about 3% penetration of PPI (搜索) script volume within gastroenterology, with the overall PPI market representing about 110 million prescriptions. Approximately 20 million prescriptions are written by gastroenterologists or advanced practice providers in gastroenterology practices.
"Phathom believes it can convert 20% to 30% of that GI PPI (搜索) script volume to VOQUEZNA," Basta stated, estimating this would correspond to "roughly 4 million to 6 million prescriptions and about $1 billion in revenue just coming out of the GI scripts." He added that stabilization of patients in GI practices can later lead to refills in primary care, representing "an additional upside opportunity over time."
Pipeline Development and Exclusivity Strategy
The company is advancing an eosinophilic esophagitis (搜索) (EoE) program, which Basta highlighted as potentially the "largest economic driver" through exclusivity extension opportunities. He noted that "first-line therapy for EoE today is PPIs" and that a multicenter, well-controlled trial could generate important data for EoE care while providing additional benefits including a "halo effect" in GI relationships.
Discussions with the FDA indicated that EoE would be "an indication of interest in pediatric patients under 2023 FDA guidance for pediatric exclusivity extension." If the Phase II trial reads out positively and supports advancing to Phase III, Phathom would expect to discuss including adolescent patients in the Phase III program and potentially obtain a written request that could qualify for a six-month exclusivity extension.
Intellectual Property Protection
Basta explained that the company's exclusivity is primarily driven by standard new chemical entity (NCE) exclusivity, extended to 10 years through the GAIN Act because the drug's first approval was for an anti-infective indication in H. pylori. This exclusivity is reflected in the Orange Book and runs through May 2032, preventing an abbreviated new drug application (ANDA) from being filed until that date.
An early generic launch could occur in early 2033 if an ANDA review proceeded quickly, though multiple review cycles could extend effective exclusivity into 2034. All of these dates could potentially be extended by six months with pediatric exclusivity.
Financial Position and Strategic Outlook
The company's recent capital raise was intended primarily to "reset" the balance sheet amid what Basta described as a significant debt overhang. He pointed to investor concerns related to debt coming due in 2027 and noted the company has a "really big interest expense line" on its profit and loss statement. The company hopes to use the raise to improve its capital structure, including potential refinancing or renegotiation of debt terms.
Looking ahead, Phathom is evaluating longer-term business development opportunities to leverage its gastroenterology-focused commercial infrastructure. The company will look over the next one to three years for products with clear human efficacy data at least through Phase II, a primary GI call point, and launch timing before the company's loss of exclusivity date.